Document is current
Any future updates will be listed below
-
Authors
Yamada, Yuto
Yamauchi, Yusuke
Sakamoto, Shinji
Fujiwara, Masaki
Okahisa, Yuko
Takao, Soshi
Takaki, Manabu https://orcid.org/0000-0002-7371-2821
Yamada, Norihito
-
Funding
Funding for this research was provided by:
Dopamine Partial Agonist Society
- License Information
-
More Information
Article History
Received: 21 September 2021
Accepted: 16 February 2022
First Online: 21 February 2022
Declarations
:
: N.Y. has received unrestricted research funding from Daiichi Sankyo, Eisai, Pfizer, Otsuka, Astellas, and Merck Sharp & Dohme, which was deposited into research accounts at Okayama University. N.Y. has received honoraria for his participation as a speaker at educational events from UCB Japan, Tsumura, Pfizer, Dainippon-Sumitomo, Daiichi-Sankyo, Merck Sharp & Dohme, Pfizer, Eisai, Meiji-Seika, and Mochida.M.T. has received honoraria for his participation as a speaker at educational events sponsored by Otsuka, Dainippon Sumitomo, and Takeda.S.S. has received unrestricted research funding from Eli Lilly, which was deposited into research accounts at Okayama University Hospital. S.S. has received honoraria for his participation as a speaker at an educational event sponsored by Otsuka.Y. Yamada, Y. Yamauchi, M.F., Y.O., and S.T. report no additional financial or other relationship relevant to this article.
